Assessing the maxillary sinus mucosa of rabbits in the presence of biodegradable implants

André Coura Perez1, Armando da Silva Cunha Junior2, Silvia Ligório Fialho3, Lívia Mara Silva4, João Vicente Dorgam5, Adriana de Andrade Batista Murashima6, Alfredo Ribeiro Silva7, Maria Rossato8, Wilma Terezinha Anselmo-Lima9

Abstract

In an attempt to improve the quality of life of patients with vitreous humor disease, ophthalmologists began offering steroid-eluting biodegradable implants to their patients. These implants can be used as an alternative treatment for CRS and this is why this experimental study was carried out on rabbit maxillary sinuses.

Objective: This study aims to assess the histology of the mucosa of the maxillary sinuses of rabbits after the placement of a prednisolone-eluting biodegradable implant.

Method: Eighteen rabbits were randomly divided into two groups: group 1 - subjects had drug-eluting implants placed on their left maxillary sinuses; group 2 - subjects had non-drug-eluting implants placed on their left maxillary sinuses. The right maxillary sinuses served as the controls. After seven, 14, and 28 days three rabbits in each group were randomly picked to have their tissue inflammatory response assessed.

Results: Levels of mucosal inflammation were not significantly different between the groups with and without drug-eluting implants and the control group, or when the groups with drug-eluting implants and non-drug-eluting implants were compared.

Conclusion: Signs of toxicity or mucosal inflammation were not observed in the maxillary sinuses of rabbits given prednisolone-eluting implants or non-drug-eluting implants.

Keywords: drug implants, histology, prednisolone, sinusitis.
INTRODUCTION

Chronic rhinosinusitis (CRS) is one of the most common health problems to affect the population. Health care costs incurred in to treat this condition are significant. About 135 in every 1,000 people in the United States - or 31 million people - are affected every year at a total cost of 6 billion US dollars1-3.

The pathophysiology of CRS is uncertain to this date, and the most widely accepted theory around it states that it is a multifactorial chronic inflammatory disease possibly associated with genetic predisposition. Some of the related factors include: biofilm, osteitis, allergy, immune disorders, upper airway intrinsic factors, Staphylococcus aureus super antigens, eosinophilic inflammation produced by fungal infection, and metabolic disorders such as hypersensitivity to aspirin3.

Many inflammatory patterns are believed to be involved with CRS and that they may differ depending on the postoperative prognosis3,4.

Various therapies have been suggested for patients with CRS. High grade evidence indicates that topical nasal steroids, systemic steroids, and low-dosage macrolides on long term regimens are effective in managing CRS. Functional endoscopic sinus surgery (FESS) may be an alternative to patients failing to respond to the medical treatment5.

The lack of knowledge on the actual pathophysiology of CRS translates into difficulties finding a curative therapy, thus depositing additional importance on patient compliance and treatment preferences. Mode of administration, type of medication, total cost of treatment and side effects must always be considered.

Intraocular injections of steroids are a frequent nuisance in the lives of patients with vitreous humor disease. In order to spare them from the injections, ophthalmologists have been offering steroid-eluting biodegradable implants to their patients6,7.

The presence of a methyl (CH3) group in the lactic acid chain of PLGA confers greater hydrophobicity to the biomaterial when compared to byproducts containing greater amounts of glycolic acid (PGA). Therefore, PGA is quite sensitive to hydrolysis and unfit to be used in PDRS. As it concerns PLGA, the greater the levels of lactic acid, the more hydrophobic the copolymer, the less water it absorbs, and the slower it degrades. Additionally, molecular weight and degree of crystallinity may impact the mechanical properties, hydrolytic capacity, and degradation rates of these polymers9.

PDRS using PLGA with high contents of lactic acid - characterized by lower degradation rates - may result in systems in which drug release occurs for periods of time as long as three years, depending on production parameters and external variables related to the tissue in which it is placed14. Thus, the development of these systems may mean significant progress, once they are able to keep drug concentrations on the desired site within therapeutic levels for a long period of time15-19. Many drugs may be conveyed using implants, such as antibiotics, antiviral drugs, chemotherapy agents, and steroids, with satisfactory results in eye care according to recently published papers, in which implant degradation in the vitreous did not lead to damage to eye tissues6,8,13.

The most frequently used biodegradable polymers are polyesters such as caprolactone, o polyactic acid (PLA) and various lactic and glycolic acid copolymer types (PLGA), the latter two being extensively used22.

PLA and the different types of PLGA have been widely used and studied in prolonged drug delivery systems (PDRS) in various human tissues. Biodegradation of these polymers occurs by erosion, cleavage of the polymer chain by hydrolysis with the consequent release of lactic and glycolic acids. These acids are natural metabolites and are eliminated by the Krebs cycle in the form of carbon dioxide and water (Figure 1)13.

![Figure 1. Hydrolysis mechanism of PLA, PGA or PLGA (adapted from Merkli et al.19).](image)

The presence of a methyl (CH3) group in the lactic acid chain of PLGA confers greater hydrophobicity to the biomaterial when compared to byproducts containing greater amounts of glycolic acid (PGA). Therefore, PGA is quite sensitive to hydrolysis and unfit to be used in PDRS. As it concerns PLGA, the greater the levels of lactic acid, the more hydrophobic the copolymer, the less water it absorbs, and the slower it degrades. Additionally, molecular weight and degree of crystallinity may impact the mechanical properties, hydrolytic capacity, and degradation rates of these polymers9.

PDRS using PLGA with high contents of lactic acid - characterized by lower degradation rates - may result in systems in which drug release occurs for periods of time as long as three years, depending on production parameters and external variables related to the tissue in which it is placed14. Thus, the development of these systems may mean significant progress, once they are able to keep drug concentrations on the desired site within therapeutic levels for a long period of time15-19. Many drugs may be conveyed using implants, such as antibiotics, antiviral drugs, chemotherapy agents, and steroids, with satisfactory results in eye care according to recently published papers, in which implant degradation in the vitreous did not lead to damage to eye tissues6,8,13.
Implants may become a good alternative treatment to CRS, as once in contact with the paranasal sinus mucosa they may facilitate treatment and patient compliance, acting as a substitute for the daily application of topical steroids. Therefore, this study aims to assess the histology of the mucosa of the maxillary sinuses of rabbits after the placement of a prednisolone-eluting biodegradable implant.

METHOD

This study included 18 female New Zealand rabbits weighing between 2.5 and 3.5 Kg kept in cages in the animal lab of the Ribeirão Preto Medical School of the University of São Paulo (FMRP-USP). The 18 subjects were randomly divided into two groups.

In the preparation of the biodegradable implants, prednisolone and PLGA (75:25) were weighed on a ratio of 21-26/79-74% and then solubilized on proper solvent and distilled water. The solution was then filtered using a sterile 0.2 mm filter under laminar flow. Next it was frozen dried, and used to prepare hot-molded rod-shaped implants. The implants weighed between 0.9 and 1.2 mg, measured 4.5 to 6.0 mm in length, and had diameters ranging between 0.4 and 0.5 mm (Figure 2A). The low coefficient of variation between the implants was indicative of the reproducibility of the employed technique. Macroscopically, the implants were similar smooth monolithic systems with steroids scattered within the polymer matrix. The surface and outer shape of the implants were examined on an scanning electron microscope (SEM). Surface images were captured at magnification powers ranging from 250 to 5,000 times (Figure 2B-C).

Surgical Procedure

The rabbits were anesthetized with intramuscular xylazine hydrochloride (20 mg/Kg) and ketamine hydrochloride (10 mg/Kg). The nasal dorsum of the rabbits was cleaned with iodine. A sagittal incision of approximately 5 cm on the midline of the nasal dorsum down to the periosteum was performed (Figure 3A-B). The periosteum on both sides of the nasal dorsum were detached with a Paparella ear tube to expose the bone suture on the midline and the anterior wall of both maxillary sinuses (Figure 3C). Chisel and hammer were used to produce 25x8 mm rectangular bone-mucosal flaps on the anterior wall of both maxillary sinuses, with the larger axis running parallel to the midline bone suture. The medial border of the flap was 3 mm away from the midline bone suture and the upper border 3 to 5 mm below the frontal-maxillary suture (Figure 3D). The macroscopic aspect of the maxillary sinus mucosa was observed with the aid of a headlight.

The rabbits were divided into two groups. Group 1 subjects had prednisolone-eluting biodegradable implants placed on their left maxillary sinuses; the same procedure was carried out in their right maxillary sinuses (Figure 3E); Group 2 had non-drug-eluting biodegradable implants placed on their left maxillary sinuses; the same procedure was carried out in their right maxillary sinuses, but no implants were inserted.
The right maxillary sinuses of both groups were used as controls. After this stage, the bone flaps were put in place again to mitigate invasion on sinus tissue and the subjects' skin was stitched closed with nylon 4-0 wire to ensure tight contact between the periosteum and subcutaneous tissue (Figure 3F). The site of the procedure was again cleaned with iodine and subjects were administered intramuscular ketoprofen (10mg/kg) for two days and enrofloxacin (0.1 ml/kg) for three days.

The experimental protocol employed in this study was approved by the Animal research Ethics Committee at FMRP-USP (permit nº 132/2010).

After seven, 14, and 28 days three rabbits were randomly picked from each group and slaughtered under general anesthesia as described above. Their facial mesostructure was removed in a block resection and placed in 10% formaldehyde for further histological analysis (Figure 4A-B). For histology analysis purposes, the specimens were placed in a formaldehyde solution (10% w/v) and were left for six days in a solution of nitric acid (5% w/v) for decalcification. Serial cross-sectional slices from the nose to the skull were made every two centimeters (Figure 4C-E); then they were dehydrated, clarified, and embedded in paraffin. Next, the specimens were cut on a microtome in 5 µm thick slices, and stained in hematoxylin-eosin to assess tissue inflammatory response patterns.

The slides were analyzed by the same pathologist using a semiquantitative approach. The examiner was blinded for the groups to which the slides belonged, and rated them as per the adopted criteria for inflammation: 0 = no inflammation; 1 = mild inflammation (scattered inflammatory cells, no evident epithelial lesion); 2 = moderate inflammation (dense diffuse inflammatory infiltrate in the lamina propria, no formation of inflammatory aggregates, presence of focal epithelial cell lesion characterized by disorganized ruptured epithelial cells); 3 = severe inflammation (dense diffuse inflammatory infiltrate with formation of inflammatory aggregates and diffuse epithelial cell lesion characterized by disorganized ruptured epithelial cells)20.

Software package SPSS (Statistical Package for Social Sciences) release 19.0 was used to process raw data and produce statistical results. A statistical significance level of 5% (0.05) was adopted in statistical tests.

RESULTS

Seven rabbits in Group 1 (prednisolone-eluting biodegradable implants on left maxillary sinuses) did not present signs of mucosal inflammation; two were slaughtered on day 7, three on day 14, and two on day 28 after implantation. Only two, one slaughtered on day 7 and another on day 28 after implantation, had mild and moderate inflammation respectively (Figure 5). Severe inflammation was observed in the right maxillary sinuses (control side) of two rabbits slaughtered seven days after implantation, whereas the rest of the group had no signs of inflammation (Table 1). Mild mucosal inflammation was observed in one of the rabbits slaughtered seven days after implantation and in two slaughtered on day 14 in Group 2 (non-drug-eluting biodegradable implants on left maxillary sinuses). Moderate mucosal inflammation was seen in two rabbits slaughtered on days 7 and 28 respectively (Figure 5A-B). Only one subject slaughtered on day 28 had severe inflammation. The remaining subjects did not have signs of inflammation. Four rabbits in Group 2 (controls) did not have right maxillary sinus mucosal inflammation. Mild inflammation was observed in three subjects; moderate inflammation in one and severe in another slaughtered on day 28 (Table 2).
Table 1. Histological assessment of inflammation on mucosas of rabbits in Group 1.

| Subjects | Right maxillary sinus (control) | Left maxillary sinus | Time to slaughter |
|----------|---------------------------------|----------------------|------------------|
| C13      | 0                               | (I + P) 0            | 7 days           |
| C17      | 0                               | (I + P) 1            | 7 days           |
| C18      | 0                               | (I + P) 0            | 7 days           |
| C1       | 0                               | (I + P) 0            | 14 days          |
| C2       | 0                               | (I + P) 0            | 14 days          |
| C3       | 0                               | (I + P) 0            | 14 days          |
| C6       | 3                               | (I + P) 2            | 28 days          |
| C7       | 3                               | (I + P) 0            | 28 days          |
| C8       | 0                               | (I + P) 0            | 28 days          |

0: no inflammation; 1: mild inflammation; 2: moderate inflammation; 3: severe inflammation; (I+P): prednisolone-eluting biodegradable implant.

Table 2. Histological assessment of inflammation on mucosas of rabbits in Group 2.

| Subjects | Right maxillary sinus (control) | Left maxillary sinus | Time to slaughter |
|----------|---------------------------------|----------------------|------------------|
| C14      | 0                               | (I) 1                | 7 days           |
| C15      | 1                               | (I) 0                | 7 days           |
| C16      | 0                               | (I) 2                | 7 days           |
| C10      | 0                               | (I) 0                | 14 days          |
| C11      | 1                               | (I) 1                | 14 days          |
| C12      | 1                               | (I) 1                | 14 days          |
| C4       | 0                               | (I) 0                | 28 days          |
| C5       | 2                               | (I) 2                | 28 days          |
| C9       | 3                               | (I) 3                | 28 days          |

0: no inflammation; 1: mild inflammation; 2: moderate inflammation; 3: severe inflammation; (I): biodegradable implant without prednisolone.

Table 3. Inflammation pattern in controls and sinuses with biodegradable implants.

|                  | Sinuses with biodegradable implants | Total |
|------------------|-------------------------------------|-------|
|                  | N        | Y        |       |
| Controls         | 8        | 3        | 11    |
|                  | 44.40%   | 16.70%   | 61.10%|
|                  | 2        | 5        | 7     |
|                  | 11.10%   | 27.80%   | 38.90%|
|                  | 10       | 8        | 18    |
|                  | 55.60%   | 44.40%   | 100.00%|

No statistically significant differences were noted on inflammatory patterns when the mucosas of the maxillary sinuses receiving the implants with and without prednisolone were compared to their controls.

**Description and comparison between implants with and without steroids**

Fisher's exact test was used to verify possible differences between implants with and without steroids for variable 'inflammation' in two categories (Table 4). A trend indicative of lesser mucosal inflammation in the rabbits given the implant with steroids was found when the mucosas of the maxillary sinuses of rabbits receiving the implants with prednisolone were compared to the mucosas of the subjects receiving the implants without prednisolone, as the calculated p-value sat between 5% (0.050) and 10% (0.100).

Table 4. Inflammation pattern in maxillary sinuses with and without prednisolone.

| Implants      | Inflammation | Total |
|---------------|--------------|-------|
|               | N    | Y    |       |
| P             | 7    | 2    | 9     |
| Non-P         | 3    | 6    | 9     |
|               | 10   | 8    | 18    |
|               | 55.60%| 44.40%| 100.00%|

* p = 0.077.

**Effect of variable ‘slaughter time’**

A verisimilitude ratio test was applied to verify possible differences between the three times at which the rabbits were slaughtered when compared concurrently for the variables of interest (Tables 5 and 6). No statistically significant differences were found in mucosal inflammation when the groups receiving implants with and without steroids were compared to...
On a first study done in 2006\textsuperscript{7} and in another two carried out in 2007 and 2008, Fialho et al.\textsuperscript{8,10} showed that steroid-eluting biodegradable implants placed on the vitreous of rabbits’ eyes did not lead to toxicity or significant inflammatory response, as similarly seen in the mucosas of the paranasal sinuses of the rabbits included in this study. However, it is worthy noting that in the ENT area this is the first study to describe the use of biodegradable implants as a means to provide controlled release of medication (prednisolone) onto paranasal sinuses.

This study was limited to assessing the inflammation these implants could introduce to the mucosas of the maxillary sinuses of rabbits. Other parameters need to be further studied, such as the proper concentration of the drug on the implant and the ideal amount of polymer to allow for optimal implant degradation and, consequently, the amount of medication to be released onto the target organ, the best implant size to reach each specific goal, and how much drug could be absorbed systemically. This is key information for the future development of implants that can be safely placed in humans as seen in ophthalmic care.

This study has been the first step toward the development of a possible treatment for CRS.

**CONCLUSION**

Although this is a preliminary study, we may state that the implants with and without steroids did not cause toxicity or inflammation to the maxillary sinus mucosas of rabbits.

**REFERENCES**

1. Benninger MS, Ferguson BJ, Hadley JA, Hamilos DL, Jacobs M, Kennedy DW, et al. Adult chronic rhinosinusitis: definitions, diagnosis, epidemiology, and pathophysiology. Otolaryngol Head Neck Surg. 2003;129(3 Suppl):S1-32.
2. Osguthorpe JD. Adult rhinosinusitis: diagnosis and management. Am Fam Physician. 2001;63(1):69-76.
3. Fokkens W, Lund V, Mullol J; European Position Paper on Rhinosinusitis and Nasal Polyps Group. EP3OS 2007: European position paper on rhinosinusitis and nasal polyps 2007. A summary for otorhinolaryngologists. Rhinology. 2007;45(2):97-101.
4. Voegels RL, de Melo Pádua FG. Expression of interleukins in patients with nasal polyposis. Otolaryngol Head Neck Surg. 2005;132(4):613-9.
5. Ragab SM, Lund VJ, Scadding G. Evaluation of the medical and surgical treatment of chronic rhinosinusits: a prospective, randomised, controlled trial. Laryngoscope. 2004;114(5):925-9.
6. Fialho SL, Silva Cunha A. Manufacturing techniques of biodegradable implants intended to intraocular application. Drug Deliv. 2005;12(2):109-16.
7. Fialho SL, Rêgo MB, Siqueira RC, Jorge R, Haddad A, Rodrigues AL, et al. Safety and pharmacokinetics of an intravitreal biodegradable implant of dexamethasone acetate in rabbit eyes. Curr Eye Res. 2006;31(3):525-34.

**DISCUSSION**

The exact pathogenesis of CRS is yet unknown. Numerous conservative and surgical treatments have been tried without, in many cases, successfully curing patients with the disease. Given that this is a chronic ailment, in which patient compliance to the treatment is essential, the authors of this study decided to try a new mode of delivering the drug to the patients’ diseased paranasal sinus mucosas, so that they would no longer have to take daily topical or systemic medication and improve treatment efficacy. Biodegradable implants could be an excellent option: patients would have implants inserted in the mucosa of their noses or paranasal sinuses that carried the proper drug at the ideal therapeutical concentration, without the need to remove them later, as they would be absorbed by the patients’ bodies.

### Table 5. Inflammation pattern in control sinuses vs. time to slaughter.

| Time to slaughter | Control Sinus | Total |
|-------------------|---------------|-------|
|                   | No            | Yes   |      |
| 7 days            | 5             | 1     | 6    |
|                   | 83.30%        | 16.70%| 100.00%|
| 14 days           | 4             | 2     | 6    |
|                   | 66.70%        | 33.30%| 100.00%|
| 28 days           | 2             | 4     | 6    |
|                   | 33.30%        | 66.70%| 100.00%|
| Total             | 11            | 7     | 18   |
|                   | 61.10%        | 38.90%| 100.00%|

*p = 0.185.*

### Table 6. Inflammation pattern in sinuses with biodegradable implants vs. time to slaughter.

| Time to slaughter | Sinus with biodegradable implant | Total |
|-------------------|----------------------------------|-------|
|                   | No                               | Yes   |      |
| 7 days            | 3                                | 3     | 6    |
|                   | 50.00%                           | 50.00%| 100.00%|
| 14 days           | 4                                | 2     | 6    |
|                   | 66.70%                           | 33.30%| 100.00%|
| 28 days           | 3                                | 3     | 6    |
|                   | 50.00%                           | 50.00%| 100.00%|
| Total             | 10                               | 8     | 18   |
|                   | 55.60%                           | 44.40%| 100.00%|

*p = 0.796; P: with prednisolone; non-P: no prednisolone; Y: (yes) inflammation present; N: (no) inflammation absent.*

controls, or when the group receiving the implants with prednisolone was compared to the group receiving the implants without steroids.
8. Fialho SL, Siqueira RC, Jorge R, Silva-Cunha A. Biodegradable implants for ocular delivery of anti-inflammatory drug. J Drug Del Sci Tech. 2007;17(1):93-7.

9. Fialho SL, Cunha Júnior Ada S. Drug delivery systems for the posterior segment of the eye: fundamental basis and applications. Arq Bras Oftalmol. 2007;70(1):173-9.

10. Fialho SL, Behar-Cohen F, Silva-Cunha A. Dexamethasone-loaded poly(ε-caprolactone) intravitreal implants: A pilot study. Eur J Pharm Biopharm. 2008;68(3):637-46.

11. Dash AK, Cudworth GC 2nd. Therapeutic applications of implantable drug delivery systems. J Pharmacol Toxicol Methods. 1998;40(1):1-12.

12. Jain R, Shah NH, Malick AW, Rhodes CT. Controlled drug delivery by biodegradable poly(ester) devices: different preparative approaches. Drug Dev Ind Pharm. 1998;24(8):703-27.

13. Merkli A, Tabatabay C, Gurny R, Heller J. Biodegradable polymers for the controlled release of ocular drugs. Prog Polym Sci. 1998;23(3):563-80.

14. Saettone MF, Salminen L. Ocular inserts for topical delivery. Adv Drug Deliv Rev. 1995;16(1):95-106.

15. Hashizoe M, Ogura Y, Kimura H, Moritera T, Honda Y, Kyo M, et al. Scleral plug of biodegradable polymers for controlled drug release in the vitreous. Arch Ophthalmol. 1994;112(10):1580-4.

16. Zhou T, Lewis H, Foster RE, Schwendeman SP. Development of a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy. J Control Release. 1998;55(2-3):281-95.

17. Tan DT, Chee SP, Lim I, Theng J, Van Ede M. Randomized clinical trial of Surodex steroid drug delivery system for cataract surgery: anterior versus posterior placement of two Surodex in the eye. Ophthalmology. 2001;108(12):2172-81.

18. Kimura H, Ogura Y, Hashizoe M, Nishiwaki H, Honda Y, Ikada Y. A new vitreal drug delivery system using an implantable biodegradable polymeric device. Invest Ophthalmol Vis Sci. 1994;35(6):2815-9.

19. Sakurai E, Nozaki M, Okabe K, Kunou N, Kimura H, Ogura Y. Scleral plug of biodegradable polymers containing tacrolimus (FK506) for experimental uveitis. Invest Ophthalmol Vis Sci. 2003;44(11):4845-52.

20. Ozcan KM, Ozcan I, Selcuk A, Akdogan O, Gursen SG, Deren T, et al. Comparison of Histopathological and CT Findings in Experimental Rabbit Sinusitis. Indian J Otolaryngol Head Neck Surg. 2011;63(1):56-9.